Adverse events following immunization of elderly with COVID-19 inactivated virus vaccine (CoronaVac) in Southeastern Brazil: an active surveillance study

Healthcare workers, the elderly and other vulnerable populations were the first to receive COVID-19 vaccines in public health programs. There were few vaccine safety data available on the elderly. This observational study aimed to evaluate the inactivated vaccine (CoronaVac) safety in the elderly, at the beginning of the vaccination program, in Sao Paulo city, Brazil. The elderly people that received CoronaVac at the Reference Center for Special Immunobiologicals (CRIE) or at home, administered by the Interdisciplinary Home Care Team (NADI) of the Hospital das Clinicas were invited to participate in this phase 4 observational study. The vaccination schedule included two CoronaVac doses 28 days apart. The information on solicited and unsolicited adverse events following immunization were collected by phone calls on days 4 and 8 after each vaccine dose. We enrolled 158 adults aged 65 to 101 years (mean of 84.1 years); 63.9% were females and 95.6% had chronic conditions, 21.5% had moderate or severe impairment in daily living activities; 34.2% were pre-frail and 19.6% were frail. We were able to contact 95.6% and 91.6% of the vaccinated people, after the first and second doses, respectively; 31.8% and 23.4% of the contacted participants reported some adverse events (AE) following the first and second doses, respectively. Pain at the injection site, fatigue, myalgia and headaches were the most frequent solicited AE. Most AE were mild to moderate. There were eight severe adverse events, but none of them were considered related to the vaccine. The CoronaVac was safe and well tolerated by these adults of advanced age with frailty and comorbidities.

Palavras-chave

COVID-19 vaccine, Inactivated vaccine, Safety, Adverse events, Elderly, Postmarketing product surveillance

URI

https://observatorio.fm.usp.br/handle/OPI/50544

Referências

Brasil. Ministerio da Saude, DATASUS
Brasil. Ministerio da Saude, PAINEL CORONAVIRUS
Bueno SM, 2022, CLIN INFECT DIS, V75, pE792, DOI 10.1093/cid/ciab823
Castro MC, 2021, SCIENCE, V372, P821, DOI 10.1126/science.abh1558
Choi YY, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e318
Ensrud KE, 2008, ARCH INTERN MED, V168, P382, DOI 10.1001/archinternmed.2007.113
Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1126/science.abh2644Article, 10.1101/2021.02.26.21252554]
Instituto Butantan, CORONAVAC
KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016
Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3
RUBENSTEIN LZ, 1984, J AM GERIATR SOC, V32, P503, DOI 10.1111/j.1532-5415.1984.tb02235.x
Sao Paulo. Secretaria da Saude, VACINOMETRO
Lino VTS, 2008, CAD SAUDE PUBLICA, V24, P103, DOI 10.1590/S0102-311X2008000100010
Strandberg TE, 2007, LANCET, V369, P1328, DOI [10.1016/S0140-6736(07)60613-8, 10.1016/S0140-6736(12)62167-9]
Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X
United State. Food and Drug Administration, TOX GRAD SCAL HLTH
Uppsala Monitoring Centre, US WHO UMC SYST STAN
Victora C, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101036
World Health Organization, BACKGR DOC IN VACC S
Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7

Coleções

Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/12
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - LIM/48

Carregar mais

Página do item completo